Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

The cyclin-dependent kinases pathway as a target for prostate cancer treatment: rationale and future perspectives
Nicole Brighi, Vincenza Conteduca, Cristian Lolli, et al.
Critical Reviews in Oncology/Hematology (2020) Vol. 157, pp. 103199-103199
Closed Access | Times Cited: 21

Showing 21 citing articles:

SHR and SCR coordinate root patterning and growth early in the cell cycle
Cara M. Winter, Pablo Székely, Vladimir Popov, et al.
Nature (2024) Vol. 626, Iss. 7999, pp. 611-616
Open Access | Times Cited: 16
Oximes: Novel Therapeutics with Anticancer and Anti-Inflammatory Potential
Igor A. Schepetkin, М. Б. Плотников, Аndrei I. Khlebnikov, et al.
Biomolecules (2021) Vol. 11, Iss. 6, pp. 777-777
Open Access | Times Cited: 57
Second generation androgen receptor antagonists and challenges in prostate cancer treatment
Yanhua Chen, Qianqian Zhou, William Hankey, et al.
Cell Death and Disease (2022) Vol. 13, Iss. 7
Open Access | Times Cited: 56
Unravelling the molecular mechanisms of prostate cancer evolution from genotype to phenotype
Dali Tong
Critical Reviews in Oncology/Hematology (2021) Vol. 163, pp. 103370-103370
Closed Access | Times Cited: 24
Cannabidiol Inhibits the Proliferation and Invasiveness of Prostate Cancer Cells
Eve O’Reilly, Karima Khalifa, Joanne Cosgrave, et al.
Journal of Natural Products (2023) Vol. 86, Iss. 9, pp. 2151-2161
Open Access | Times Cited: 7
Circulating tumor cell gene expression and plasma AR gene copy number as biomarkers for castration-resistant prostate cancer patients treated with cabazitaxel
Giorgia Gurioli, Vincenza Conteduca, Nicole Brighi, et al.
BMC Medicine (2022) Vol. 20, Iss. 1
Open Access | Times Cited: 11
CDK4/6 Alters TBK1 Phosphorylation to Inhibit the STING Signaling Pathway in Prostate Cancer
Wei Li, Feng Guo, Ruijiang Zeng, et al.
Cancer Research (2024) Vol. 84, Iss. 16, pp. 2588-2606
Closed Access | Times Cited: 1
Mechanisms of abemaciclib, a CDK4/6 inhibitor, induced apoptotic cell death in prostate cancer cells in vitro
Gamze Güney Eskiler, Asuman Deveci Özkan, Ayten Haciefendi, et al.
Translational Oncology (2021) Vol. 15, Iss. 1, pp. 101243-101243
Open Access | Times Cited: 13
The role of cyclins in the development and progression of prostate cancer
Joanna Dulińska-Litewka, Dominik Felkle, Kacper Dykas, et al.
Biomedicine & Pharmacotherapy (2022) Vol. 155, pp. 113742-113742
Open Access | Times Cited: 9
Newly developed preclinical models reveal broad‐spectrum CDK inhibitors as potent drugs for CRPC exhibiting primary resistance to enzalutamide
Takashi Matsuoka, Aiko Sugiyama, Yoshifumi Miyawaki, et al.
Cancer Science (2023) Vol. 115, Iss. 1, pp. 283-297
Open Access | Times Cited: 3
Unravelling the Role of Kinases That Underpin Androgen Signalling in Prostate Cancer
Katie Joanna Miller, Mohammad Asim
Cells (2022) Vol. 11, Iss. 6, pp. 952-952
Open Access | Times Cited: 6
Preparation and cytotoxic evaluation of new steroidal oximes and aza-homosteroids from diosgenin and cholesterol
Thalía Lissette Mora-Medina, Roxana Martinez‐Pascual, M. A. Peña-Rico, et al.
Steroids (2022) Vol. 182, pp. 109012-109012
Closed Access | Times Cited: 5
Recent progress and controversies in the treatment of metastatic hormone-sensitive prostate cancer

Journal of Men s Health (2024) Vol. 20, Iss. 6, pp. 1-1
Open Access
Roles of CDK12 mutations in PCa development and treatment
Chen Jiang, Zhe Hong, Shiwei Liu, et al.
Biochimica et Biophysica Acta (BBA) - Reviews on Cancer (2024), pp. 189247-189247
Closed Access
Combined Ribociclib and NU7026 administration enhances radio-sensitivity by inhibiting DNA repair in prostate cancer
Jinbo Sun, Yong Wang, Shanjin Ma, et al.
Naunyn-Schmiedeberg s Archives of Pharmacology (2024)
Closed Access
The Activation of the CCND1 Promoter by AP-1 and SOX Transcription Factors in PC3 Prostate Cancer Cells Can Be Prevented by Anacardic Acid Analogs
Manon Brunie, Marc Robichaud, Mohamed Touaibia, et al.
Cell Biochemistry and Biophysics (2024)
Closed Access
Targeting ADAR1 with a Novel Small-Molecule for the Treatment of Prostate Cancer
Xiao Wang, Jiaxing Li, Yasheng Zhu, et al.
Research Square (Research Square) (2021)
Open Access | Times Cited: 4
Immunogenomic profiles associated with response to life-prolonging agents in prostate cancer
Vincenza Conteduca, Nicole Brighi, Giuseppe Schepisi, et al.
British Journal of Cancer (2023) Vol. 129, Iss. 7, pp. 1050-1060
Closed Access | Times Cited: 1
Oncogenic Proteomics Approaches for Translational Research and HIV-Associated Malignancy Mechanisms
Eduardo Alvarez-Rivera, Emanuel J. Ortiz-Hernández, Elyette Lugo, et al.
Proteomes (2023) Vol. 11, Iss. 3, pp. 22-22
Open Access
Metastasiertes kastrationsresistentes Prostatakarzinom – Was kommt neues
Gunhild von Amsberg, Tilman Todenhöfer
Deleted Journal (2023) Vol. 62, Iss. 12, pp. 1289-1294
Closed Access
Src kinase: An attractive therapeutic target for prostate cancer
Rajnikant Raut, Parth Gupta, Taruna Saini, et al.
Elsevier eBooks (2022), pp. 479-503
Closed Access
Page 1

Scroll to top